Retatrutide NEW

Get Latest Price

Min. Order1KG
Purity99
Cas No2381089-83-2
Supply Ability100 KG
Update time2026-10-09

Hangzhou Lucky Biology Co., Ltd

VIP2Y

China

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Manufacturer

Chemical Properties

Product Name	Retatrutide
CAS No	2381089-83-2
EC-No
Min. Order	1KG
Purity	99
Supply Ability	100 KG
Release date	2026/10/09

Generic Name	Retatrutide
Development Code	LY3437943
Developer	Eli Lilly and Company
CAS Number	2381089-83-2
Molecular Formula	C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight	~4731 Da
Compound Class	Peptide — triple GIP/GLP-1/Glucagon receptor agonist ("Triple G")
Route of Administration	Subcutaneous injection, once weekly
Regulatory Status	Not yet approved; NDA/BLA filing planned for 2027

Retatrutide is a synthetically designed 39-amino-acid single-chain peptide based on the GIP backbone. It incorporates non-natural amino acid substitutions (Aib², Aib²⁰, αMeLeu¹³) to enhance metabolic stability and optimize receptor activity. A C20 fatty diacid moiety is conjugated via a linker at the lysine¹⁷ residue to extend its circulating half-life, enabling once-weekly subcutaneous dosing.

🧪 General Information

Item	Details
Generic Name	Retatrutide
Development Code	LY3437943
Developer	Eli Lilly and Company
CAS Number	2381089-83-2
Molecular Formula	C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight	4731 Da
Compound Class	Peptide — triple GIP/GLP-1/Glucagon receptor agonist ("Triple G")
Route of Administration	Subcutaneous injection, once weekly
Regulatory Status	Not yet approved; NDA/BLA filing planned for 2027

📐 Structural Description

🔬 Mechanism of Action

Retatrutide is the first-in-class triple GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and GCG (glucagon) receptor agonist. By simultaneously activating all three incretin/metabolic hormone receptors, it achieves synergistic effects across multiple pathways:

GLP-1 receptor — Suppresses appetite, delays gastric emptying, and enhances glucose-dependent insulin secretion
GIP receptor — Amplifies insulinotropic effects, improves insulin sensitivity, and enhances lipid metabolism
Glucagon receptor (GCGR) — Increases energy expenditure, promotes hepatic fatty acid oxidation, and reduces liver fat content

This triple-action mechanism enables a "reduce intake + boost metabolism + burn fat" approach, distinguishing it from single-agonist (e.g., semaglutide) and dual-agonist (e.g., tirzepatide) therapies.

Dosage Forms

Retatrutide is formulated as a lyophilized powder for reconstitution, available in strengths including 4 mg, 9 mg, and 12 mg for subcutaneous injection. Dosing follows a stepwise titration schedule to minimize gastrointestinal side effects.